Weight loss drugs like Wegovy and Zepbound carry list prices between $1,000 and $1,350 per month in the United States, making them some of the most expensive prescription medications many people will ever encounter. The high cost isn’t driven by any single factor. It’s a combination of complex manufacturing, strong patent protections, a fragmented insurance landscape, and a pricing system unique to the U.S. that allows drugmakers to set prices far above what other wealthy countries pay for the same medications.
What These Drugs Actually Cost
A month’s supply of Wegovy at its maintenance dose lists at $1,349 in the U.S. Zepbound, made by Eli Lilly, lists at roughly $1,000 per month. These are “list prices,” meaning the wholesale price the manufacturer charges before any insurance negotiations or discounts. What you actually pay depends heavily on your coverage. Patients with commercial insurance that covers one of these drugs may pay as little as $25 per month through manufacturer savings programs. But if your plan doesn’t cover the drug, or you don’t have insurance, you’re looking at something close to that full list price plus pharmacy fees.
That sticker shock becomes even more striking when you consider these drugs are designed to be taken indefinitely. Stop taking them, and most people regain a significant portion of the weight they lost. So the real cost isn’t just one month. It’s years of monthly refills.
Manufacturing Biologics Is Genuinely Expensive
These medications aren’t simple pills pressed from chemical powders. Semaglutide (the active ingredient in Wegovy) and tirzepatide (in Zepbound) are biologics, meaning they’re produced using living cells rather than straightforward chemical reactions. The manufacturing process requires designing specialized cell lines, maintaining tightly controlled production environments, and running extensive quality checks to ensure each batch is consistent.
Bringing a generic version of a biologic (called a “biosimilar”) to market is also far more expensive than copying a traditional pill. A company can’t simply replicate the chemical formula. It has to develop an entirely new cell line and manufacturing process that produces a nearly identical molecule, then often run large clinical trials to prove the copy works just as well. This higher barrier to entry means fewer competitors, which keeps prices elevated longer than they might be for a standard generic drug.
That said, manufacturing costs alone don’t explain a $1,300 monthly price tag. Production technology for biologics has been improving in efficiency for years, and the actual cost of producing these molecules is a fraction of what patients pay.
Patents Keep Competitors Out
Novo Nordisk holds U.S. patents on semaglutide until 2032, giving it roughly seven more years of market exclusivity in America. No generic or biosimilar version can legally enter the U.S. market until those patents expire. Eli Lilly holds similar protections on tirzepatide.
The global picture is different. Semaglutide patents are set to expire in India, China, and Brazil in March 2026, and generic manufacturers in those countries are already preparing to enter the market. But for American consumers, patent protection means the two dominant drugmakers face limited direct competition for the foreseeable future, removing the main force that drives drug prices down.
Americans Pay Several Times More Than Other Countries
The price gap between the U.S. and other wealthy nations is enormous, and it’s one of the clearest signs that manufacturing costs aren’t the primary driver of American prices. A month of Wegovy costs $1,349 in the U.S. compared to $328 in Germany and $296 in the Netherlands. A month of the diabetes version, Ozempic, runs $936 here versus $93 in the United Kingdom, $83 in France, and $96 in Sweden. That’s roughly a tenfold difference for the exact same drug.
The reason is structural. Most other wealthy countries have government bodies that negotiate drug prices directly with manufacturers, often refusing to pay above a threshold tied to how much health benefit a drug actually delivers. The U.S. has historically not done this for most medications. Drugmakers can set their own list prices, and while insurers negotiate discounts behind the scenes, those discounts don’t always reach the patient. The result is that Americans effectively subsidize lower prices in the rest of the world, paying the highest sticker price in any major market.
Middlemen Take a Cut and Add Complexity
Between the manufacturer and your pharmacy sits a layer of intermediaries called pharmacy benefit managers, or PBMs. These companies negotiate rebates on behalf of insurance plans, and those rebates can be substantial. For GLP-1 drugs specifically, manufacturer discounts have been estimated at 40% to 60% of the list price. In theory, those savings should lower what you pay. In practice, the system is opaque. PBMs may retain a portion of the rebate rather than passing it all through to the insurer or patient, and the negotiation process can actually incentivize higher list prices. A manufacturer might set a high list price knowing it will offer a large rebate, because PBMs sometimes favor drugs with bigger rebates regardless of the net cost.
This means the “real” price paid for these drugs is often much lower than the list price, but uninsured patients and those with high-deductible plans get stuck paying closer to the inflated number. The system works reasonably well for patients with good coverage and poorly for everyone else.
Insurance Gaps Make It Worse
Even having insurance doesn’t guarantee coverage. Many commercial plans exclude weight loss medications entirely, treating them as lifestyle drugs rather than treatments for a chronic disease. The situation is particularly stark for the 67 million Americans on Medicare. Federal law currently prohibits Medicare Part D from covering drugs used solely for weight loss. If you’re on Medicare and want Wegovy specifically for obesity, it’s not covered.
There is one workaround: in 2024, the FDA approved Wegovy to reduce the risk of major cardiovascular events in patients who have both obesity (or overweight) and existing cardiovascular disease. Medicare can cover it for that specific combination of conditions. And the Centers for Medicare and Medicaid Services proposed a rule in late 2024 that would reinterpret the statutory exclusion to allow Part D coverage of anti-obesity medications when used to treat obesity as a disease. If finalized, that would be a significant shift, but as of now, the exclusion remains the default for most Medicare enrollees.
The lack of broad insurance coverage creates a two-tiered system. People with generous employer-sponsored plans may pay $25 a month. People on Medicare, Medicaid, or skimpier commercial plans may pay full price or simply go without.
The Long-Term Cost Problem
One argument for covering these drugs is that treating obesity should save money downstream by preventing diabetes, heart disease, joint replacements, and other expensive conditions. That logic holds for surgical weight loss procedures, which have high upfront costs but consistently prove cost-effective or even cost-saving over five to ten years because the weight loss is durable.
GLP-1 drugs present a different equation. Because most patients need to keep taking them to maintain their results, the cumulative cost can eventually surpass even the price of bariatric surgery. At current prices, a decade of Wegovy would cost over $160,000 at list price. Unless drug prices come down substantially, the long-term economic case for these medications is harder to make than it is for a one-time surgical intervention, even though the drugs are far less invasive.
This tension is at the center of the policy debate. The drugs clearly work, producing 15% to 20% or more body weight loss in clinical trials. But at current U.S. prices, the math strains household budgets and insurance systems alike. Meaningful price relief likely depends on some combination of patent expirations bringing biosimilar competition, policy changes expanding government negotiating power, and broader insurance mandates that increase the number of covered patients and give insurers more leverage to negotiate lower rates.